<DOC>
	<DOCNO>NCT00533897</DOCNO>
	<brief_summary>The purpose study determine whether subcutaneous abatacept administer patient rheumatoid arthritis associate increased immunogenicity increase safety event upon withdrawal reintroduction .</brief_summary>
	<brief_title>Phase IIIB Subcutaneous Missed Dose Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Clinical diagnosis Rheumatoid Arthritis Disease Activity Score ( DAS ) 28CReactive Protein ( CRP ) score ≥ 3.2 ≤5.1 On background methotrexate least 3 month ( ≥10mg weekly ) Must able self injection allow care giver Discontinue Biologics DiseaseModifying Antirheumatic Drugs ( DMARDs ) except methotrexate Participants prior exposure abatacept CTLA4 Ig Received treatment rituximab . Participants receive treatment leflunomide within 1 year screening Participants receive treatment immunoadsorption column ( Prosorba column ) , mycophenolate mofetil ( Cellcept® ) , cyclosporine A calcineurin inhibitor , DPenicillamine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Rheumatoid Arthritis ( RA )</keyword>
</DOC>